Genetics of Hyperuricemia Therapy in Hmong (NCT02371421) | Clinical Trial Compass
CompletedNot Applicable
Genetics of Hyperuricemia Therapy in Hmong
United States80 participantsStarted 2014-06
Plain-language summary
To pursue this objective, we will be measuring uric acid at baseline and post 14 days of twice daily allopurinol therapy in 30 Hmong participants with documented gout or hyperuricemia and known genotype for key renal transporters of uric acid.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Both parents are Hmong (self report)
* Self report history of gout, or
* History (within one year) of active use of xanthine oxidase inhibitors, or
* Evidence of serum uric acid ≥ 6mg/dL , or
* Serum uric acid \< 6mg/dL with history of ≥ 2 gout episodes within the last 6 months
* Ability to provide informed consent for participation in the study
* Demonstrate understanding of the study procedures and ability to comply with the study drug for the entire length of the study
* Ability to obtain permission from treating clinician to allow stopping the drug for 10 days
Exclusion Criteria:
* Pregnant women or women of childbearing age sexually active and not using any contraception
* estimated creatinine clearance (eCrCl) \<30ml/min
* Elevated liver enzymes (3 x upper normal limit of liver function tests (AST and ALT))
* Contraindication to receiving allopurinol
* Active participation in other clinical trial (or within 30 days)
What they're measuring
1
Percent change from baseline in serum uric acid
Timeframe: 14 days
2
Steady state oxipurniol area under the serum concentration-time curve (AUC)